Autor(es):
Kissling, Esther ; Nunes, Baltazar ; Robertson, Chris ; Valenciano, Marta ; Reuss, Annicka ; Larrauri, Amparo ; Cohen, Jean Marie ; Oroszi, Beatrix ; Rizzo, Caterina ; Machado, Ausenda ; Pitigoi, Daniela ; Domegan, Lisa ; Paradowska-Stankiewicz, Iwona ; Buchholz, Udo ; Gherasim, Alin ; Daviaud, Isabelle ; Horváth, Judit Krisztina ; Bella, Antonino ; Lupulescu, Emilia ; O Donnell, Joan ; Korczyńska, Monika ; Moren, Alain ; I-MOVE case–control study team
Data: 2016
Identificador Persistente: http://hdl.handle.net/10400.18/4254
Origem: Repositório Científico do Instituto Nacional de Saúde
Assunto(s): Influenza; influenza Virus; Vaccine-preventable Diseases; Vaccines and Immunisation; Estados de Saúde e de Doença; Determinantes da Saúde e da Doença
Descrição
Since the 2008/9 influenza season, the I-MOVE multicentre case-control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0-65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1-15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9-67.9) and remained between this value and 50.3% (95% CI: 34.8-62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3-82.4) 44 days after vaccination to 21.4% (95% CI: -57.4-60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
